Biotech

All Articles

Merck ceases phase 3 TIGIT test in bronchi cancer cells for impossibility

.Merck &amp Co.'s TIGIT plan has actually experienced one more problem. Months after shuttering a st...

After a tough year, Exscientia folds up right into Recursion

.After a year described through pipeline hairstyles, the shift of its own chief executive officer as...

Cullinan, after $25M bargain, hands back bispecific to Harbour

.Cullinan Therapy was impressed enough with Harbour BioMed's bispecific invulnerable activator that ...

A deeper consider Brutal Biotech's Strong 15

.In this particular full week's incident of "The Leading Pipe," our company're diving into Ferocious...

Lilly faces stage 2 failing of tau-targeting med

.The confetti is actually still flying coming from Eli Lilly's celebration celebrating the commendat...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our roundup of substantial leadership hirings, firings ...

Lykos will definitely ask FDA to reexamine its own decision following being rejected of MDMA treatment for post-traumatic stress disorder

.Adhering to a poor presenting for Lykos Therapies' MDMA applicant for trauma at a recent FDA consul...

AN 2 fifty percents headcount, ceases phase 3 test after information let down

.AN2 Rehabs is actually rethinking its business in feedback to dull midphase information, vowing to ...

Merck spends $700M for bispecific, snooping autoimmune position and odds to test Amgen in cancer

.Merck &amp Co. is paying out $700 thousand beforehand to test Amgen in a blood cancer cells market....

Gilead pays for J&ampJ $320M to leave licensing offer for seladelpar

.With Gilead Sciences about to an FDA selection for its liver illness drug seladelpar, the business ...